Overview

Patients with diabetes are also much more likely to suffer from cardiovascular disease than those without diabetes. In fact, cardiovascular disease is the leading cause of death associated with diabetes – certainly a medical double jeopardy. The American Diabetes Association’s (ADA) recently published the 2017 Standards of Medical Care in Diabetes and included new recommendations on treating both diabetes and cardiovascular disease. Pharmacists are often the medical professional that patients reach out to for guidance and explanation on new pharmaco-therapy and individualized treatment. This program will review the ADA’s latest update to the Standards of Medical Care in Diabetes, review recent outcomes trials of antihyperglycemic therapies in patients with type 2 diabetes (T2D) and outline evidence based treatment strategies to mitigate the risk of cardiovascular disease in patients with T2D. 

Handouts

Financial Support By

PharmCon

Repeat Presentation

This presentation was last given on 9/23/2019 2:00 PM

Future Airings

Activity Type

Knowledge

CE Broker

Universal Activity Number

Pharmacist 0798-0000-18-265-L01-P

Pharmacy Technician 0798-0000-18-265-L01-T

Nurse 0798-0000-18-265-L01-N

PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Faculty

Tamara  Goldberg, PharmD, BCPS Associate Professor of Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences Long Island University